Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that over the past 12 months Genedata Screener has experienced unprecedented industry adoption with 7 out of the 25 leading pharmaceutical companies using Screener for High Content Screening (HCS) analysis. Screener’s HCS capabilities support complex multiplexed assay formats, enable comparative visualization of HCS images and help standardize processes from a centrally managed platform. The announcement was made at the 7th Annual High Content Analysis Conference where Genedata is presenting and exhibiting (January 11 – 15; Fairmont Hotel - Booth # 27).
“HCS analysis within a high throughput screening infrastructure is evolving and 2009 proved to be the year in which we saw leading pharmaceutical companies understand how they can use Screener’s HCS capabilities in conjunction with their high throughput screening workflows,” said Dr. Othmar Pfannes, CEO of Genedata. “These companies have quickly transitioned from the learning – enlightenment phase to actual production in which data analysis is no longer a bottleneck in high content screening.”
Genedata customers, who rely on Screener for high content confirmation and secondary screens, are beginning to use Screener for HCS at high throughputs. Several customers report that Screener HCS enables them to easily process 1,000,000 compounds or more per screen. This is a result of Screener’s ability to leverage this information within a scalable framework, which features automated data processing and intelligent management functions - all of which can be reviewed by scientists at any stage in the process. “2009 was a banner year for HCS adoption,” continued Pfannes, “and I project that 2010 will be the year in which we see HCS in far more rigorous production settings as well as continued adoption by customers looking for a scalable HCS technology.”
Screener standardizes and automates in-depth analysis of high content screens passing from single-cell data to hit selection in a highly efficient workflow. The increased throughput of Screener HCS and user-friendly interface for visualization, management, and review allows researchers and scientists to review more cellular images in less time and quickly identify subtle variances. While Screener is fully compatible with the Thermo Scientific Cellomics Store image management system, it has also been integrated with other in-house and commercial HCS image storage solutions.
Note to Editors: Genedata will deliver a presentation on how to establish a routine application of HCS in high throughput screening at HCA on January 13th at 1:00 p.m. To schedule an editorial briefing, email Jackie.Thrasivoulos@genedata.com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.